CAGE Bio Launches Phase 2 Trial for Innovative Vitiligo Treatment CGB-600 CAGE Bio has begun a pivotal Phase 2 clinical trial for CGB-600, a revolutionary DNA Aptamer treatment aimed at improving outcomes for vitiligo patients.

CAGE Bio Launches Phase 2 Trial for Innovative Vitiligo Treatment CGB-600 #USA #San_Carlos #Vitiligo #CAGE_Bio #CGB-600

CAGE Bio's Phase 2b Trial Shows Promising Results for Atopic Dermatitis Treatment CAGE Bio announces significant results from its Phase 2b trial of CGB-500, showing high effectiveness in treating atopic dermatitis with a favorable safety profile.

CAGE Bio's Phase 2b Trial Shows Promising Results for Atopic Dermatitis Treatment #United_States #Atopic_Dermatitis #San_Carlos #CAGE_Bio #CGB-500

CAGE Bio Partners with Mayo Clinic to Innovate Treatments for GvHD CAGE Bio has joined forces with Mayo Clinic to develop new therapies for chronic graft-versus-host disease, addressing critical patient needs.

CAGE Bio Partners with Mayo Clinic to Innovate Treatments for GvHD #USA #Mayo_Clinic #San_Carlos #CAGE_Bio #GvHD